Ekspresi Annexin A2 pada Kanker Ginekologi

William Alexander Setiawan

Abstract


Tujuan: Untuk menentukan adanya hubungan antara ekspresi ANXA2 dan berbagai aspek kanker ginekologi.
Metode: Pencarian terstruktur untuk penelitian yang menyelidiki hubungan ekspresi ANXA2 dan kanker serviks, kanker endometrium dan kanker ovarium menggunakan PubMed. Pencarian terbatas pada 10 tahun terakhir dan dilakukan penyaringan dengan kriteria inklusi serta eksklusi yang telah ditetapkan.
Hasil: Dari 52 penelitian didapatkan 9 penelitian yang kemudian dilakukan telaah kritis. ANXA2 diekspresikan berlebih dalam jaringan karsinoma dibandingkan dengan jaringan normal.
Kesimpulan: Peningkatan ekspresi ANXA2 berperan dalam proliferasi sel kanker. Ekspresi ANXA2 berkorelasi dengan stadium lanjut dan penyakit metastasis. ANXA2 dapat digunakan untuk memprediksi progresivitas, angka kelangsungan hidup, dan resistensi terhadap rejimen pengobatan.


Annexin A2 Expression in Gynecological Cancer: A Systematic Review

Abstract
Objective: To determine the relationship between ANXA2 expression and various aspects of gynecological cancer.
Method: A structured search for studies involving the relationship of ANXA2 and cervical cancer, endometrial cancer and ovarian cancer using PubMed. Search is limited to the last 10 years and is screened with predetermined inclusion and exclusion criteria.
Result: Of the 52 studies obtained 9 studies which were then carried out critical studies. ANXA2 is overexpressed in carcinoma tissue compared to normal tissue.
Conclusion: Increased expression of ANXA2 approved in cancer cell proliferation. Expression of ANXA2 correlates with advanced stage and metastatic disease. ANXA2 can be used to predict progression, survival rates, and resistance to treatment regimens.

Key words: Annexin A2, gynecological cancer, proliferation


Keywords


Annexin A2; kanker ginekologi, proliferasi

Full Text:

PDF

References


Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74. doi: 10.1200/JCO.2010.33.4235

Jin L, Shen Q, Ding S, Jiang W, Jiang L, Zhu X. Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 Jul;126(1):140-6. doi: 10.1016/j.ygyno.2012.04.005

Choi CH, Chung JY, Chung EJ, Sears JD, Lee JW, Bae DS, Hewitt SM: Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer. BMC Cancer 16: 448, 2016. doi: 10.1186/s12885-016-2459-y

Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, et al. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One. 2012;7(8): e43519. doi: 10.1371/journal.pone.0043519

Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang H, et al. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res. 2015 Sep 11;34:96. doi: 10.1186/s13046-015-0208-8

Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, et al. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. 2015 Apr 15;136(8):1863-73. doi: 10.1002/ijc.29213

Lokman NA, Pyragius CE, Ruszkiewicz A, Oehler MK, Ricciardelli C. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Transl Res. 2016 May;171:83-95.e1-2. doi: 10.1016/j.trsl.2016.02.002

Deng Y, Chen C, Hua M, Xi Q, Liu R, Yang S. Annexin A2 plays a critical role in epithelial ovarian cancer. Arch Gynecol Obstet. 2015 Jul;292(1):175-82. doi: 10.1007/s00404-014-3598-5

Lokman NA, Elder AS, Ween MP, Pyragius CE, Hoffmann P, Oehler MK, et al. Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. oncotarget 4: 1199-1211, 2013. doi: 10.18632/oncotarget.1122

Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, et al. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine. 2017 Apr;13(3):1183-1193. doi: 10.1016/j.nano.2016.11.015




DOI: http://dx.doi.org/10.24198/obgynia/v4n1.174

Refbacks

  • There are currently no refbacks.


Alamat Redaksi

 

KSM/Dep Obstetri & Ginekologi Fakultas Kedokteran Universitas Padjadjaran RSUP Dr. Hasan Sadikin

Jl. Pasteur No 38 Bandung 40161 

Telp: 0813-2012-9954

Email: obgyniajurnal@gmail.com

 

 

 




Indexed By
         



Web Analytics
View My Stats

Indonesian Journal of Obstetrics & Gynecology Science @2017